The medications include Abbott Laboratories inc's Lupron, AstraZeneca Plc's Zoladex and Sanofi-Aventis SA's Eligard.

Sanofi spokeswoman Emmy Tsui said the company was "committed to the safe and effective use of Eligard" and was reviewing the FDA request.